-

05:17:14 PM

Latest CEMI Stock Market News

CEMI - Chembio Diagnostics Inc.

07/22/21 5:03 PM

Nasdaq : CEMI

conferencesearnings

Chembio Diagnostics to Report Second Quarter 2021 Financial Results on August 5, 2021

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the second quarter of 2021 after the close of trading on Thursday,

RHEA-AI

neutral

07/22/21 12:49 PM

Nasdaq : CEMI

Chembio Diagnostics Receives $4 Million HIV Test Purchase Order Supported by The Global Fund

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $4 million purchase order from the Partnership for Supply Chain Management (PFSCM), supported by

RHEA-AI

neutral

07/20/21 10:56 PM

Nasdaq : CEMI

Chembio Diagnostics Receives $28.3 Million Purchase Order from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, announced its receipt today of a $28.3 million purchase order from Bio-Manguinhos for the purchase of Chembio’s DPP SARS-CoV-2

RHEA-AI

neutral

05/06/21 4:05 PM

Nasdaq : CEMI

earnings

Chembio Diagnostics Reports First Quarter 2021 Financial Results

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter ended March 31, 2021. Chembio achieved first quarter 2021 total revenue of $8.7

RHEA-AI

positive

04/22/21 8:00 AM

Nasdaq : CEMI

conferencesearnings

Chembio Diagnostics to Report First Quarter 2021 Financial Results on May 6, 2021

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the first quarter of 2021 after the close of trading on Thursday,

RHEA-AI

neutral

04/01/21 5:30 PM

Nasdaq : CEMI

covid-19

Chembio Announces U.S. Commercial Launch of Diagnostic Tool to Differentiate COVID-19 and Flu

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on

RHEA-AI

neutral

03/11/21 4:05 PM

Nasdaq : CEMI

earnings

Chembio Diagnostics Reports Fourth Quarter and Full Year 2020 Financial Results

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, today reported financial results for the quarter and year ended December 31, 2020. Recent Accomplishments & Highlights Achieved

RHEA-AI

positive

03/08/21 8:00 AM

Nasdaq : CEMI

management

Chembio Diagnostics Appoints Industry Leader David Bespalko to its Board of Directors

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the appointment of David Bespalko to the Company’s Board of Directors, effective upon his election on March 4,

RHEA-AI

very positive

02/25/21 4:05 PM

Nasdaq : CEMI

conferencesearnings

Chembio Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostics company focused on infectious diseases, announced today that it will release financial results for the fourth quarter and full year 2020 after the close of trading on

RHEA-AI

neutral

01/14/21 7:00 AM

Nasdaq : CEMI

Chembio Diagnostics Announces CE Mark for DPP SARS-CoV-2 Antigen and IgM/IgG Test Systems

Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leading point-of-care diagnostic company focused on infectious diseases, today announced the CE mark for the DPP SARS-CoV-2

RHEA-AI

very positive

CEMI Data

industryPharmaceutical Preparation Manufacturing
websitewww.chembio.com
ceo
security nameChembio Diagnostics Inc.
issue typecs
sectorManufacturing
sic code2834
employees355
tagsHealth Technology,Medical Specialties,Manufacturing,Pharmaceutical Preparation Manufacturing
address
address2
state
city
zip
country
phone

CEMI Description:

Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases, including COVID-19, sexually transmitted disease, and fever and tropical disease. Coupled with Chembio's extensive scientific expertise, its novel DPP technology offers broad market applications beyond infectious disease. Chembio's products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.